Trial Profile
Phase I/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable high grade gliomas patients
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Temozolomide
- Indications Glioblastoma; Glioma
- Focus Adverse reactions; Therapeutic Use
- Acronyms OLA-TMZ-RTE-01
- 06 Jun 2023 Results (n=30) of phase 1 step assessing safety and efficacy of olaparib combined with radiotherapy plus temozolomide in high grade glioma patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 08 Feb 2023 Planned End Date changed from 4 Sep 2023 to 4 Oct 2024.
- 08 Feb 2023 Planned primary completion date changed from 4 Mar 2023 to 4 Apr 2024.